ACM
ACET icon

ADAR1 Capital Management’s Adicet Bio ACET Stock Holding History

ADAR1 Capital Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-53,827
Closed -$367K – 278
2026
Q1 		$367K Sell
53,827
-74,819
-58% -$560K 0.02% 225
2025
Q4 		$1.08M Buy
+128,646
New +$1.42M 0.08% 126
2024
Q2 		– Sell
-1,952
Closed -$73.4K – 267
2024
Q1 		$73.4K Buy
+1,952
New +$80.8K 0.02% 162

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

ADAR1 Capital Management's ACET Position: Q2 2026 in Review

ADAR1 Capital Management sold out of Adicet Bio (ACET) in Q2 2026, closing a stake of 53,827 shares — an estimated $367K sold.

ADAR1 Capital Management first reported a position in ACET in Q1 2024 and held it in 3 quarters. The position peaked at $1.08M in Q4 2025. 56 funds tracked by Wall St. Rank hold ACET as of Q2 2026.

  • ADAR1 Capital Management reported no remaining Adicet Bio position as of Q2 2026 after selling out during the quarter.
  • ADAR1 Capital Management sold 53,827 Adicet Bio shares in Q2 2026, an estimated $367K.
  • ADAR1 Capital Management first reported a position in Adicet Bio in Q1 2024 and held it in 3 quarters.
  • ADAR1 Capital Management's Adicet Bio position peaked at $1.08M in Q4 2025.
  • 56 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.